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Abstract Cardiovasculardiseases are frequent amongpatientswiththe obstructive sleep apnoea syndrome (OSAS).
The aetiopathogenesis of this association is unclear.Type1plasminogen activator inhibitor (PAI-1) is one of the primary
regulators of the ¢brinolytic system. A reported association between PAI-1 activity and an insertion/deletion poly-
morphism (4G/5G) inthe promoter region ofthe PAI-1gene suggests a criticalrole for thisgenomic region inthepatho-
genesis of several cardiovascular diseases. In this study, we determined the prevalence of this polymorphism in patients
with OSAS and in healthy control subjects. The 4G/5G polymorphism in the promoter region of the PAI-1 gene was
determined in 78 male patientswith severe OSAS (5672 apnoeasperhour) and in 70 healthymale, non-smokervolun-
teers of similar age, without personal or familial history of cardiovascular disease.The frequency of the 4G/4G,4G/5G
and 5G/5G genotypesinpatientswith OSAS (18%,62%,19%, respectively) wasnot signi¢cantlydi¡erent fromthat seen
in healthy subjects (16%, 60%, 24% P=NS).These results show that the distribution of the 4G/5G polymorphism in the
promoter region of the PAI-1gene in patientswith OSAS is similar to thatobserved in healthy subjects.This observation
suggests that the PAI-1polymorphism has no relationship with the increased risk of cardiovascular diseases seen in pa-
tientswith OSAS.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1239, available online athttp://www.idealibrary.comon
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The prevalence of cardiovascular diseases is increased in
patients with the obstructive sleep apnoea syndrome
(OSAS) (1^3). However, the mechanisms underlying this
association are unclear (4,5).
In the general population, basic research and prospec-
tive cohort studies clearly indicate that an impaired ¢bri-
nolytic function is an important marker of
cardiovascular risk (6,7). For instance, over-expression
of the type1plasminogen activator inhibitor (PAI-1), one
of the primary regulators of the ¢brinolytic system, en-
hances the pathological deposition of ¢brin and facili-
tates the occurrence of thrombotic events (8). An
insertion/deletion polymorphism in the promoter
region of this gene, where one allele sequence has
four guanosines (4G) instead of ¢ve (5G), is associatedReceived16 May 2001and accepted in revised form 24October 2001.
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PAI-1 levels in plasma (10). A recent meta-analysis
showed that this 4Gallele is associatedwith an increased
risk ofmyocardial infarction, particularly in high-risk po-
pulations (11).
In patients with OSAS, Rangemark et al. found in-
creased PAI-1 levels and decreased ¢brinolytic activity
(12). To date, however, the distribution of the 4G/5G
PAI-1gene polymorphism in these patients has not been
investigated. In the present study we compared the fre-
quency distribution of the genotypes 4G/4G, 4G/5G and
5G/5G of the PAI-1 gene in patients with OSAS and in
healthy subjects.
METHODS
Subjects and ethics
We studied 78 consecutive male patients, younger than
65 years, with excessive daytime somnolence and a
number of apnoeas plus hypopnoeas per hour of
sleep [apnoea^hypopnea index (AHI)] higher than 20.
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(Ultrasom Nicolett, Wisconsin, U.S.A.), which included
recording of oro-nasal £ow (thermocouples), thoraco-
abdominal movements (strain gauges), electrocardio-
gram, submental electromyogram, electroculogram,
electroencephalogram (C4-A1, C3-A2) and transcuta-
neous SaO2 (Criticare Systems Inc, Waukesha, U.S.A.).
We excluded patients with chronic diseases such as
COPD, diabetes mellitus, renal failure, thyroid dys-
function and/or psychiatric disorders. As a control group
we studied 70 healthy, non-smoker, male volunteers.
None of them had personal or familiar history of
cardiovascular disease or diabetes, nor was receiving
any type of medication. In control subjects, OSAS
was excluded clinically by the criteria of Kapuniai et al.
(13). None of them snored habitually and/or reported
excessive daytime sleepiness.
All participants signed the informed consent, after
being fully aware of the nature and characteristics of
the study.This investigation was approved by the Ethics
Committee of our hospital.
Extraction and ampli¢cation of genomic
DNA
DNA was extracted from whole blood samples
obtained by venipuncture of a peripheral vein in the
arm, using the Genomic Puri¢cation System (Promega,
Madison, WI, U.S.A.) following the manufacturer’s
protocol. Samples were preserved at801C until analy-
sis. The PAI-1 promoter 4G/5G genotype was deter-
mined by the polymerase chain reaction (PCR), as
described before (14), using four di¡erent primers. Two
of these are speci¢c for the insertion 5G allele (5’-GTC
TGG ACA CGT GGG GG-3’) or deletion 4G allele (5’-
GTC TGG ACACGTGGGGA-3’) and give rise to a139
base-pair DNA fragment in combinationwith a common
downstreamprimer (5’-TGC AGCCAGCCACGTGAT
TGT CTA G-3’). A fourth primer (5’-AAG CTT TTA
CCA TGG TAA CCC CTG GT-3’) located upstream
of the polymorphic region is used as a positiveFIG. 1. Representative agarose gel showing the PCR ampli¢ed bas
genotypes (139 bp), a positive control (208 bp) and the DNAmolecul
trophoresiswasperformed as indicated in the Methods section.control to verify the occurrence of DNA ampli¢cation
in the absence of the allele on the genomic DNA. The
ampli¢ed DNA fragments were separated by agarose
gel electrophoresis (3%) with 1TAE bu¡er, stained
with ethidium bromide and viewed under ultraviolet
light (Fig.1).
Statistical analysis
Results are presented as mean7SEM or percentage (for
the genotype frequency distribution).Groups were com-
paredusing anunpaired t-test or a chi-square test, as ap-
propriate. A P-value lower than 005 was considered
signi¢cant.
RESULTS
The mean age of patients with OSAS (5271 years) was
similar to that of healthy subjects (4871years). Patients
weremore obese than controls (bodymass index (BMI):
33 170  5kgm2 vs. 25 270  3kgm2, Po0  001)
and had higher blood pressure values (systolic blood
pressure: 14372 vs. 12272mmHg, Po0  001; and dia-
stolic blood pressure: 8971vs. 7671mmHg, Po0  001).
All patients had severe OSAS, with a mean apnoea^
hypopnoea indexof 5672h1and frequent andprofound
episodes of arterial desaturation (mean nocturnal SaO2,
9371%). Thirteen of them had been diagnosed of sys-
temic hypertension and two had an acute myocardial in-
farction in the past.
Table 1 presents the distribution of PAI-1 genotypes
and alleles, which were similar in patients with OSAS
and in healthy subjects. There was no signi¢cant di¡er-
ence between the PAI-1 genotype distribution in hyper-
tensive (n=48) and non-hypertensive patients (n=30).
DISCUSSION
The main ¢nding of this study is that the 4G/5G geno-
type and allele distribution of the promoter region of
the PAI-1 gene in patients with OSAS is similar to thate-pair DNAfragments (bp) corresponding to the di¡erent PAI-1
arweightmarkers (M:194, 234,603 bp).PCR and agarose gel elec-
TABLE 1. Distribution of PAI-1 genotypes and alleles in pa-
tients and healthy subjects. No signi¢cant di¡erence exists
between groups (chi-square test)
Patientswith OSAS
(n=78)
Healthy subjects
(n=70)
Genotype 4G/4G 14 (18%) 11 (16%)
Genotype 4G/5G 49 (62%) 42 (60%)
Genotype 5G/5G 15 (19%) 17 (24%)
Allele frequency
4G 49% 46%
5G 51% 54%
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This observation suggests, therefore, that this genetic
polymorphism is not implicated in the increased
cardiovascular risk reported in OSAS.
Epidemiological studies have linked OSASwith hyper-
tension,myocardial infarction and ischaemic brain infarc-
tion, but the pathophysiological mechanisms underlying
the increased cardiovascular risk in OSAS are unex-
plained (5,15^17). Impaired ¢brinolytic function is a mar-
ker of cardiovascular risk in the general population and
PAI-1 is one of the primary regulators of the ¢brinolytic
system (6^8). There is evidence that the 4G/4G geno-
type is associated with increased circulating PAI-1 levels
(10), and several reports have examined this genotype as
a possible risk factor for coronary artery disease in dif-
ferent clinical groups (14,18^20). However, the potential
implication of the ¢brinolytic system in the pathogenesis
of cardiovascular disease in OSAS is unclear.On the one
hand, it has been reported that patients with OSASmay
exhibit elevated PAI-1levels and impaired ¢brinolytic ac-
tivity (12).On the other, our study shows that the geno-
type and allele distribution of the PAI-1gene (Table1)was
similar in patientswithOSAS and in healthy subjects.We
did not measure the activity of PAI-1 and, therefore, the
relation between PAI-1 levels and the PAI-1 promoter
4G/5G genotype cannot be established with certainty
in our patients.However, these apparently divergent re-
sults can be reconciled if the complex regulation of the
PAI-1gene is considered. For instance, the expression of
this gene is in£uencedbyboth genetic and environmental
factors. In this context, previous studies have shown that
hypoxia is a potent stimulus for the expression of the
PAI-1gene in the endothelial cells (21).The frequent epi-
sodes of oxygen desaturation that patients with OSAS
presentduring sleep can, therefore, explain ourobserva-
tion of a normal PAI-1 genotype distribution in patients
with OSAS, while previous reports have described in-
creased PAI-1 activity in the plasma of these same pa-
tients (12). Importantly, this hypothesis is testable
because, if correct, PAI-1 levels in plasma should de-
crease following optimal treatment with CPAP (whichfully prevents the episodes of oxygen desaturation that
characterizes OSAS).
In summary, our results indicate that patients with
OSAS show a similar genotype and allele distribution in
the promoter region of the PAI-1gene than healthy sub-
jects. This observation suggests that the PAI-1 poly-
morphism has no relationship with the increased risk of
cardiovascular diseases seen in patients with OSAS.
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